Press Release May 17 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Ephedrine Sulfate Injection. This injection is indicated for treating hypotension during anesthesia and will be manufactured at their facility in Jarod, India. The press release highlights that the drug had significant annual sales in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release May 10 2023
- Press Release May 04 2023
- Press Release Apr 25 2023
- Press Release Apr 24 2023
- Press Release Apr 20 2023
Later from Zydus Lifesciences
- Press Release May 18 2023
- Press Release Jun 07 2023
- Press Release Jun 08 2023
- Press Release Jun 09 2023
- Press Release Jun 10 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences